148 related articles for article (PubMed ID: 15886470)
41. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.
Akerley W; Sikov WM; Cummings F; Safran H; Strenger R; Marchant D
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-87-S17-90. PubMed ID: 9374102
[TBL] [Abstract][Full Text] [Related]
42. Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
Köppler H; Heymanns J; Weide R
Onkologie; 2001 Jun; 24(3):283-5. PubMed ID: 11455223
[TBL] [Abstract][Full Text] [Related]
43. Phase I dose-escalation trial of paclitaxel and ifosfamide in patients with advanced non-small cell lung cancer.
Shepherd FA; Latreille J; Paul K; Eisenhauer E
Semin Oncol; 1996 Dec; 23(6 Suppl 16):84-90. PubMed ID: 9007130
[TBL] [Abstract][Full Text] [Related]
44. [Weekly paclitaxel therapy for metastatic breast cancer].
Kokufu I; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K
Gan To Kagaku Ryoho; 2002 Feb; 29(2):221-6. PubMed ID: 11865627
[TBL] [Abstract][Full Text] [Related]
45. [Usefulness of weekly administration of paclitaxel for advanced or recurrent gastric cancer].
Egawa T; Kubota T; Nagashima A; Doi M; Kitano M; Hayashi S; Yoshii H; Saikawa Y; Kitajima M
Gan To Kagaku Ryoho; 2004 Jun; 31(6):877-81. PubMed ID: 15222104
[TBL] [Abstract][Full Text] [Related]
46. [Weekly administration regimen of paclitaxel (PTX) in patient with inoperable or recurrent gastric cancer].
Kii T; Takiuchi H; Gotoh M; Kawabe S; Ohta S; Tanaka T; Kuwakado S; Nishitani H; Katsu K
Gan To Kagaku Ryoho; 2006 May; 33(5):621-4. PubMed ID: 16685160
[TBL] [Abstract][Full Text] [Related]
47. [A phase II clinical study of China-made paclitaxel in the treatment of cancer patients].
Wu H; Guan Z; Lin T
Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):148-52. PubMed ID: 10920970
[TBL] [Abstract][Full Text] [Related]
48. Single-agent paclitaxel for the treatment of breast cancer: an overview.
Hortobagyi GN; Holmes FA
Semin Oncol; 1996 Feb; 23(1 Suppl 1):4-9. PubMed ID: 8629036
[TBL] [Abstract][Full Text] [Related]
49. A simplified premedication protocol for one-hour paclitaxel infusion in various combinations.
Kosmas C; Tsavaris N
Med Sci Monit; 2006 Nov; 12(11):CR462-6. PubMed ID: 17072270
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.
Ceresoli GL; Gregorc V; Cordio S; Bencardino KB; Schipani S; Cozzarini C; Bordonaro R; Villa E
Lung Cancer; 2004 May; 44(2):231-9. PubMed ID: 15084388
[TBL] [Abstract][Full Text] [Related]
51. Dose-dense therapy with paclitaxel via weekly 1-hour infusion: preliminary experience in the treatment of metastatic breast cancer.
Seidman AD; Hudis CA; McCaffrey J; Tong W; Currie V; Moynahan ME; Theodoulou M; Tepler I; Gollub M; Norton L
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-72-S17-76. PubMed ID: 9374099
[TBL] [Abstract][Full Text] [Related]
52. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.
Doz F; Gentet JC; Pein F; Frappaz D; Chastagner P; Moretti S; Vassal G; Arditti J; Tellingen OV; Iliadis A; Catalin J
Br J Cancer; 2001 Mar; 84(5):604-10. PubMed ID: 11237379
[TBL] [Abstract][Full Text] [Related]
53. Epistaxis during treatment with paclitaxel.
Yarom N; Cyjon A; Kovel S; Yachnin A; Sella A; Evron E
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):259-61. PubMed ID: 19191781
[TBL] [Abstract][Full Text] [Related]
54. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
Kloover JS; den Bakker MA; Gelderblom H; van Meerbeeck JP
Br J Cancer; 2004 Jan; 90(2):304-5. PubMed ID: 14974481
[TBL] [Abstract][Full Text] [Related]
55. Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel.
Gennari A; Salvadori B; Tognoni A; Conte PF
Ann Oncol; 1996 Nov; 7(9):978-9. PubMed ID: 9006754
[No Abstract] [Full Text] [Related]
56. Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions.
Durham CG; Thotakura D; Sager L; Foster J; Herrington JD
J Oncol Pharm Pract; 2019 Sep; 25(6):1396-1401. PubMed ID: 30419768
[TBL] [Abstract][Full Text] [Related]
57. Cross-sensitivity between taxanes in patients with breast cancer.
Sánchez-Muñoz A; Jiménez B; García-Tapiador A; Romero-García G; Medina L; Navarro V; González-Sánchez LA; Alba E
Clin Transl Oncol; 2011 Dec; 13(12):904-6. PubMed ID: 22126735
[TBL] [Abstract][Full Text] [Related]
58. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
[TBL] [Abstract][Full Text] [Related]
59. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
Horiguchi J; Rai Y; Tamura K; Taki T; Hisamatsu K; Ito Y; Seriu T; Tajima T
Anticancer Res; 2009 Feb; 29(2):625-30. PubMed ID: 19331212
[TBL] [Abstract][Full Text] [Related]
60. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
